Drug profile · INN
moexipril hydrochloride
MOEXIPRIL HYDROCHLORIDE
moexipril hydrochloride (MOEXIPRIL HYDROCHLORIDE) is a angiotensin-converting enzyme inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — moexipril hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
moexipril hydrochloride (MOEXIPRIL HYDROCHLORIDE) is a angiotensin-converting enzyme inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Angiotensin-converting enzyme inhibitor
Primary target: Angiotensin-converting enzyme
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is moexipril hydrochloride?
moexipril hydrochloride (MOEXIPRIL HYDROCHLORIDE) is a angiotensin-converting enzyme inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for moexipril hydrochloride?
MOEXIPRIL HYDROCHLORIDE is a marketed brand name for moexipril hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of moexipril hydrochloride?
moexipril hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.